Scenic Biotech

Meet us in Boston! Our CEO, Oscar Izeboud, will give a presentation tomorrow entitled “Modifier therapy: a new approach to target neuro- and metabolic disease” at 12:15 pm EST during the Biotech showcase at LSX World Congress USA. We are eager to connect for 2 days with the key players driving the future of healthcare and see the latest innovations in the field. If you are also attending and want to learn more about Scenic’s radically new approach to treating genetic disorders, reach out via the partneringONE platform!   #LSXUSA #HealthcareInnovation #LifeSciences

At Scenic, we are committed to transforming the treatment of genetic disorders through our pioneering modifier therapy. We believe in the power of connecting with communities affected by orphan and rare diseases, which is why Vincent Blomen, will be attending the Barth Syndrome Foundation (BSF) Biennial International Scientific, Medical, and Family Conference to discuss a novel therapeutic target for Barth Syndrome during the Poster Session on August 1, 2024

Today, we have announced the appointment of Ben Machielse to Scenic’s Board of Directors. Ben brings over 25 years of drug development expertise, covering all stages from preclinical evaluation to commercialization, from life science companies, including Sucampo Pharmaceuticals-acquired Vtesse and AstraZeneca-acquired Omthera Pharmaceuticals. We welcome Ben to our board and look forward to having his drug development expertise for rare diseases as we accelerate our pipeline of innovative modifier therapies toward the clinic. Read the full press release to find out more about this announcement: https://lnkd.in/dN8WZt6a

Today, we have announced the appointment of Ben Machielse to Scenic’s Board of Directors. Ben brings over 25 years of drug development expertise, covering all stages from preclinical evaluation to commercialization, from life science companies, including Sucampo Pharmaceuticals-acquired Vtesse and AstraZeneca-acquired Omthera Pharmaceuticals. We welcome Ben to our board and look forward to having his drug development expertise for rare diseases as we accelerate our pipeline of innovative modifier therapies toward the clinic. Read the full press release to find out more about this announcement: https://lnkd.in/dN8WZt6a

Our Head of Translational Research, Guido Hartmann will be leading a presentation entitled “Discovery of a novel NPC disease modifier and development towards its clinical application” at next week's NATIONAL NIEMANN-PICK DISEASE FOUNDATION Family Support & Medical Conference (NNPDF) on July 12 at 11:45 am MDT in Salt Lake City. The NNPDF conference is a unique opportunity to connect with expert clinicians, researchers, and families affected by Niemann-Pick disease.   Join us to learn about the latest advances in evolution-inspired medicine and how Scenic Biotech is pioneering modifier therapy to treat genetic disorders, including Niemann-Pick disease.   Together, as one voice, we can achieve urgently needed clinical treatments and support ongoing research towards a cure.   We look forward to seeing you there!   #NNPDF2024 #ModifierTherapy #NiemannPickDisease

Don’t miss the chance to meet Scenic’s Principal Scientist, Arthur de Jong, PhD at the Lysosomes and Endocytosis Gordon Research Conference held in Andover, New Hampshire on June 19th at 9:15 pm ET. Join Arthur’s oral presentation to learn how we have used our innovative modifier platform to identify and develop a product targeting Niemann Pick Type C that is now moving toward the clinic. 

#SavetheDate: Scenic’s Principal Scientist, Arthur de Jong, PhD will be discussing how we are using our unique modifier therapy approach to develop a novel treatment option for Niemann Pick Type C disease at the Lysosomes and Endocytosis Gordon Research Conference held in Andover, New Hampshire from June 16-21.

Connect with our CMO, Jens Wuerthner, MD PhD, at the Ara Parseghian Annual Scientific Conference, in Tucson, Arizona. Join Jens’ for his presentation to learn more about how Scenic has discovered a novel disease modifier for Niemann-Pick Type C and is currently advancing our innovative pipeline program toward clinical application.

Connect with our CMO, Jens Wuerthner, MD PhD, at the Ara Parseghian Annual Scientific Conference, in Tucson, Arizona. Join Jens’ for his presentation to learn more about how Scenic has discovered a novel disease modifier for Niemann-Pick Type C and is currently advancing our innovative pipeline program toward clinical application.

Don’t miss the chance to meet Frederik Gorter de Vries, Corporate Development Scenic Biotech, at the 24th Bio€quity Europe in San Sebastián, Spain, from May 12 to 14.   To schedule a one-to-one meeting with Frederik, visit: https://lnkd.in/dYrgwkAr